Selective androgen receptor degrader (SARD) ligands and methods of use thereof

A method of treating, suppressing, reducing the incidence of, reducing the severity of, or inhibiting the progression of an androgen-dependent disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor degrader (SARD) compound represented by the structure of formula I:

• wherein
• T is OH;
• R1 is CH3;
• Y is H, CF3, F, I, Br, Cl, or CN;
• Z is H, NO2, CN, halide, COOH, COR, NHCOR, or CONHR;
• X is CH or N;
• R is H, alkyl, alkenyl, or haloalkyl;
• A is R2;
• R2 is a 5-membered unsaturated ring having at least one nitrogen atom and 1, or 2 double bonds, optionally substituted with at least one of Q1, Q2, Q3 or Q4, each independently selected from hydrogen, substituted or unsubstituted linear or branched alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, haloalkyl, substituted or unsubstituted aryl, F, Cl, Br, I, CN, NO2, OR, benzyl, NCS, NHCOOR, N(R)2, NHCOR, CONHR, COOR, or COR;
• or its optical isomer, pharmaceutically acceptable salt, or any combination thereof.